Launch Catch-Up — Research Reported October 26, 2026
University of Pennsylvania researchers reported improved muscle function in mouse models of Duchenne muscular dystrophy after using gene editing to increase production of utrophin, a protein that can perform some functions of dystrophin.
Dystrophin helps maintain healthy muscle and is deficient in people with Duchenne muscular dystrophy. The research tested whether increasing the alternative protein could help compensate, according to Penn Medicine’s October 26 account.
The team investigated delivery approaches using a muscle-targeting viral vector and messenger RNA carried in lipid nanoparticles. CRISPR-Cas9 editing increased utrophin production.
Treated mice showed stronger muscle performance and fewer disease-associated fibers. These animal findings do not establish safety or effectiveness in people, or an approved treatment for patients.
Penn said researchers are continuing work on more precise editing and alternative delivery systems. The study appeared in Molecular Therapy Advances; the announcement describes experimental research rather than results from a human clinical trial.
Sources: Penn Medicine, October 26: https://www.pennmedicine.org/news/stopping-muscular-dystrophy-with-a-backup-protein